By incorporating HSP70 targeting into nanoparticle-based therapies for GBM CSCs, researchers can address the intrinsic characteristics of CSCs and the specific molecular pathways and resistance mechanisms associated with HSP70 expression. The gene discussed is HSPA1A; the disease is glioblastoma.